10-K: Integrated BioPharma Reports Strong FY25 Growth

Integrated BioPharma, Inc. reported an 8% increase in net sales and a significant rise in net income for the fiscal year ended June 30, 2025, driven by growth in both Contract Manufacturing and Other Business Lines segments.

Summary

• Net sales increased by $4,036 thousand (8.0%) to $54,353 thousand in fiscal year 2025 from $50,317 thousand in fiscal year 2024.
• The Contract Manufacturing segment's net sales rose by $3,114 thousand (6.4%) to $51,682 thousand.
• The Other Business Lines segment's net sales increased by $922 thousand (52.7%) to $2,671 thousand.
• Gross profit improved to $5,562 thousand in fiscal year 2025 from $3,884 thousand in fiscal year 2024.
• Profit margins increased by 2.5 percentage points, from 7.7% in fiscal year 2024 to 10.2% in fiscal year 2025.
• Operating income significantly increased to $2,020 thousand in fiscal year 2025 from $251 thousand in fiscal year 2024.
• Net income surged to $808 thousand in fiscal year 2025 from $112 thousand in fiscal year 2024, an increase of $696 thousand.
• Basic and diluted net income per common share were $0.03 for fiscal year 2025, up from $0.00 in fiscal year 2024.
• Net cash provided by operating activities more than doubled to $2,065 thousand in fiscal year 2025 from $943 thousand in fiscal year 2024.
• Working capital increased to $14,515 thousand as of June 30, 2025, from $11,752 thousand as of June 30, 2024.
• The company paid off its Senior Credit Facility and secured new revolving and convertible equipment lines of credit with PNC Bank.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial performance with significant increases in net sales, profit margins, operating income, and net income. Liquidity also improved substantially. However, high customer concentration and ongoing inflationary pressures present notable risks.

Positives

• Net sales increased by 8.0% to $54,353 thousand in fiscal year 2025.
• Profit margins improved by 2.5 percentage points to 10.2% in fiscal year 2025, primarily due to increased sales volume.
• Operating income saw a substantial increase to $2,020 thousand in fiscal year 2025 from $251 thousand in the prior year.
• Net income grew significantly to $808 thousand in fiscal year 2025, up from $112 thousand in fiscal year 2024.
• Cash provided by operating activities more than doubled to $2,065 thousand in fiscal year 2025.
• Working capital increased by $2,763 thousand to $14,515 thousand as of June 30, 2025.
• The company successfully paid off its Senior Credit Facility and established new, flexible credit lines totaling $4,500 thousand.
• Selling and administrative expenses decreased by 2.5% ($91 thousand) in fiscal year 2025.
• No material weaknesses or significant deficiencies were identified in internal control over financial reporting.

Negatives

• A significant portion of consolidated net sales (84% in FY2025, 90% in FY2024) is concentrated among two customers, posing a substantial risk if any are lost.
• The company experiences a slight negative impact on margins due to inflation, including tariffs, delays in shipments, and tightened labor markets.
• The company may not be able to timely increase selling prices to customers to offset rising operating costs.
• The development and supply agreements with Herbalife terminate on December 31, 2025, and do not obligate minimum orders.
• The company has not paid dividends on common stock in the past and does not anticipate paying them in the foreseeable future.
• The common stock is thinly-traded, and a sale of a substantial number of shares could cause the price to decline.
• The company has significant uninsured deposits of $4,362 thousand as of June 30, 2025.
• An impairment charge of $28 thousand was identified on long-lived assets in fiscal year 2025.

Risks

• Revenue could decline significantly if one or more of the most significant customers are lost, as 84% of consolidated net sales are concentrated among two customers in the Contract Manufacturing Segment.
• Supply chain disruptions resulting from geo-political events, inflation (including tariffs), delays in shipments, and tightened labor markets could impact financial results and ability to meet delivery dates.
• Complying with new and existing government regulations (FDA, FTC, etc.) could significantly increase costs, require product reformulation or removal, or disrupt marketing.
• Exposure to legal proceedings initiated by regulators or third parties could increase costs and adversely affect reputation, revenues, and operating income.
• Dependence on senior management (Co-CEOs Christina Kay and Riva Sheppard, CFO Dina L. Masi, VP of Operations Mireille Antinozzi), with the loss or unavailability of their services having an adverse effect.
• Risk of cybersecurity breaches leading to loss of data, disruption of operations, regulatory penalties, reputational damage, and financial loss.
• Inability to maintain quotation on the OTCQX Best Market, potentially leading to a less liquid market on OTCQB.
• Transactions with entities controlled by officers and directors (e.g., lease of real property from Vitamin Realty) could pose conflicts of interest.
• Executive Officers and Directors collectively own approximately 82% of outstanding common stock, giving them majority voting power that may not always align with the best interests of all stockholders.
• A staggered Board of Directors could impede attempts to take over the company or change or remove management.
• Product liability insurance ($5.0 million per occurrence and aggregate) may be insufficient to cover potential claims, or future insurance may not be available on economically feasible terms.
• Inability to obtain raw materials from suppliers or at competitive pricing could decrease sales or increase cost of sales, especially with one principal supplier for the Other Business Lines Segment.
• Current economic conditions, such as reduced credit availability, financial market volatility, tariffs, recession, and tightening labor markets, could adversely affect business and financial performance.
• Incurrence of significant professional service fees and other control costs due to public company regulatory requirements, which could become a competitive disadvantage.
• Discovery of material weaknesses or other deficiencies in internal control and accounting procedures could lead to a significant decline in stock price and difficulty raising capital.
• Investors' expectations regarding environmental, social, and governance (ESG) factors may impose additional costs, expose the company to new risks, and potentially lead to reputational damage or exclusion from certain investment portfolios.
• Increased SEC scrutiny and new rules on climate-related risk disclosures (effective FY2027) could lead to increased costs and potential enforcement actions.
• Inflation and tightened labor markets may prevent the company from timely increasing selling prices to customers, impacting margins and results of operations.

Future Outlook

Management believes that current operations, combined with available credit facilities and equipment financing, will adequately support working capital requirements through at least September 18, 2026. The company plans to continue focusing on its core businesses, maintaining its cost structure in line with sales, and expanding its customer base. However, the ability to timely increase selling prices to offset rising operating costs due to inflation and tightened labor markets remains a challenge.

Management Comments

• "We believe that we have established and developed business relationships, facilities, personnel, product offerings, and competitive and financial resources in place for business success."
• "We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base."
• "We have seen a slight negative impact in our margins due to inflation and tightened labor markets as we strive to increase prices to our customers as our operating costs increase."
• "Management believes that operations, together with our credit facilities and equipment financing will support our working capital requirements at least through the twelve-month period ending September 18, 2026."

Industry Context

The nutraceutical industry is highly competitive, with many larger players possessing greater financial resources. Integrated BioPharma operates primarily in contract manufacturing and other business lines, focusing on quality, service, competitive pricing, and niche international markets. The industry is subject to stringent government regulations from agencies like the FDA and FTC, with increasing enforcement activities, particularly regarding dietary supplements. Economic conditions, including inflation and labor market tightness, continue to impact operating costs and consumer spending, posing challenges for pricing and demand across the sector.

Comparison to Industry Standards

• NA (The filing does not provide specific comparable company or project data to assess against global benchmarks.)

Management Changes

Corporate Governance

Legal Proceedings

• Not aware of any legal proceedings or claims that are believed to have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• Lease of warehouse and office facilities from Vitamin Realty Associates, LLC, which is 100% owned by the estate of the former Executive Chairman and major stockholder, and the current Co-Chief Executive Officers who are also directors.
• Rent expense, lease amortization costs, and imputed interest costs on these related party leases were $1,345 thousand for FY2025 and $1,292 thousand for FY2024.
• Operating lease obligations with Vitamin Realty were $485 thousand as of June 30, 2025, and $1,289 thousand as of June 30, 2024.

Stakeholder Impact

• Shareholders experienced increased net income and EPS, but no dividends are anticipated. The concentration of ownership by executive officers and directors (82%) could affect control and market price. The thinly-traded stock may face downward pressure from substantial share sales.
• Relations with employees are considered good, with 77% covered by a union contract expiring in August 2026. The use of a PEO for non-union employees streamlines HR administration and benefits.
• High customer concentration (84% of sales from two customers) means the loss of any major customer could significantly impact financial condition and operations. Supply chain disruptions and the inability to pass on cost increases could affect product availability and pricing.
• Improved liquidity and the payoff of the Senior Credit Facility, replaced by new lines of credit, indicate a stronger financial position for debt servicing.
• Dependence on a principal supplier for the Other Business Lines segment creates a risk if relationships cannot be maintained or alternative sourcing is not found at favorable pricing.

Next Steps

• File a definitive Proxy Statement within 120 days after the close of the fiscal year ended June 30, 2025.
• Continue to focus on core businesses and expand the customer base.
• Strive to increase prices to customers to offset rising operating costs due to inflation and tightened labor markets.
• File tax returns for the year ended June 30, 2025, by March 15, 2026.
• Budgeted capital expenditures of approximately $500 thousand for the fiscal year ending June 30, 2026, to be funded from operations and lease financing.
• Evaluate the impact of adopting ASU 2023-09 (Income Tax Disclosures) for annual periods beginning July 1, 2025.
• Evaluate the impact of adopting ASU 2024-03 (Income Statement Expense Disaggregation) for annual periods beginning July 1, 2027.

Key Dates

Recommendation

Integrated BioPharma demonstrated strong financial improvements in FY2025, with significant increases in net sales, profit margins, and net income, alongside improved liquidity. The company has also refinanced its debt, which is a positive. However, the high customer concentration (84% from two customers) presents a substantial risk, and the stock is thinly-traded. While the operational performance is commendable, these inherent risks and the lack of dividend payments suggest a 'hold' recommendation for seasoned investors, advising to monitor customer relationships and market conditions closely before further investment.

Keywords

Nutraceuticals, Vitamins, Nutritional Supplements, Herbal Products, Contract Manufacturing, SEC Filing, 10-K, Financial Results, Integrated BioPharma, INBP, OTC Markets, Supply Chain, Regulatory Compliance, Customer Concentration, Corporate Governance, Risk Management, Financial Performance, Stock Options, Working Capital, PNC Bank